NEV-801 CML Chronic Myeloid Leukemia
"During its pre-clinical proof-of-concept studies, NEV-801 showed exciting potential, including curative effects, to treat Chronic Myeloid Leukemia that had become resistant to the gold-standard therapy (imatinib), as well as advanced colon cancer that had become resistant to multiple therapies. No bone-marrow toxicity or gastro-intestinal side effects were observed at the highest administered doses in pre-clinical studies"
Extract of Seattle Biotech Neovia Begins Clinical Trial for Immunotherapy Enhancing Cancer Drug
CLINICAL TRIALS
A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers
A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers
ARTICLES
Neovia Enrolls First Patient in Cancer Trial for Immunotherapy Enhancing Drug
February 1, 2017, Yahoo Finance
Seattle Biotech Neovia Begins Clinical Trial for Immunotherapy Enhancing Cancer Drug
January 25, 2017, PRNewswire
Seattle Biotech Neovia Begins Clinical Trial for Immunotherapy Enhancing Cancer Drug
January 25, 2017, CheckOrphan
A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers
June 13, 2016, BioPortoFolio
Neovia Enrolls First Patient in Cancer Trial for Immunotherapy Enhancing Drug
February 1, 2017, Yahoo Finance
Seattle Biotech Neovia Begins Clinical Trial for Immunotherapy Enhancing Cancer Drug
January 25, 2017, PRNewswire
Seattle Biotech Neovia Begins Clinical Trial for Immunotherapy Enhancing Cancer Drug
January 25, 2017, CheckOrphan
A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers
June 13, 2016, BioPortoFolio
